Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).
about
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondAbnormal Ca(2+) cycling in failing ventricular myocytes: role of NOS1-mediated nitroso-redox balanceManagement of the cardiorenal syndrome in decompensated heart failureRight ventricular adaptation and failure in pulmonary arterial hypertension.Diagnosing and managing acute heart failure in the emergency departmentRegulation of phosphodiesterase 3 and inducible cAMP early repressor in the heartImprovement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failureChronic heart failure: contemporary diagnosis and managementInotropes do not increase mortality in advanced heart failureUse of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.Chronic inotropic therapy in end-stage heart failure.The influence of heart failure self-care on health outcomes: hypothetical cardioprotective mechanisms.Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.The interface between monitoring and physiology at the bedside.β₂ AR agonists in treatment of chronic heart failure: long path to translation.Present and future pharmacotherapy for heart failure.Nesiritide: a novel approach for acute heart failure.Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiologyProbenecid as a noninjurious positive inotrope in an ischemic heart disease murine model.Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management.Levosimendan: implications for clinicians.Management of acute decompensated heart failure in the emergency department.Acute right ventricular failure--from pathophysiology to new treatments.Inotropic agents use in patients hospitalized with acute decompensated heart failure: a retrospective analysis from a 22-year registry in a Middle-Eastern Country (1991-2013).Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model.Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure.The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studyInhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.Role of xanthine oxidoreductase in cardiac nitroso-redox imbalanceAcute heart failure: inotropic agents and their clinical uses.Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research.Comparing three life-limiting diseases: does diagnosis matter or is sick, sick?The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.Hospital patterns of use of positive inotropic agents in patients with heart failureControversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.Heart failure: chapter 8. Treatment of end-stage heart failureModulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.Clinical Characteristics and Treatment of Cardiomyopathies in Children.Decompensated heart failure.
P2860
Q24645066-A44A65D0-CCDD-408B-AE1B-7918834AABCDQ26852587-687E9A3B-D7A1-4F20-BAFA-CC4ABE62A3D5Q27028203-341034C1-5D70-4F55-B71F-32DEAD78FFE0Q27318422-2BE4B036-B5A6-4B40-B2C0-0BFA1B36E103Q28080130-6295B8D4-C20F-43E8-BC84-6772DFCB9592Q28291007-776A919A-C6F0-4DF7-8A1A-7F467090A334Q28354203-7D144B72-3305-45DC-ADBB-6A3DB431A503Q33620431-2DD32C73-D525-427A-B7BA-2CA1E6842C00Q33685748-18420C17-B6C5-4CB9-A4F8-D848BE05DD44Q33735342-3211ABC7-778D-4962-867A-08ED4E54130FQ33735360-4A444ECE-F236-4641-9977-548B5FAEDD14Q33897455-44D160C2-A557-4A03-88F6-4514931877F6Q34011572-F162DD69-BA14-40F1-9C47-4774D02FBC12Q34610360-D4548DC8-BB43-4890-9E5B-D29C5498D1B6Q34634348-1398F46D-79EC-4DB8-B983-F1FA82DC8C4BQ34706912-8D70E034-1D4D-409B-B068-521F15D946DCQ35054263-2B6F5E42-7B8D-45FB-8C48-D5C29F19BCA7Q35057072-967BEA37-C4B6-43C6-AED1-EEB24C6E426FQ35077700-9AE3B4E3-177D-4B7D-BAAD-5FD06EF25858Q35194984-F107432E-84B1-47FD-8CAE-162034F93C9FQ35200873-EB5236BF-66FD-4695-8255-E5D5FB8F6B55Q35546635-DD42A157-5F2A-48BF-9AC2-23BDE83E1E02Q35561935-13C5A488-153E-4969-9A6A-BCE4CB58DAD8Q35584099-1384F1EE-05B9-4C01-995D-0C9554F2A6E9Q35927894-F96BEB0C-8E9F-46F4-A42C-F0D0FEDF9078Q36228624-5683E235-580D-4FD0-A71F-7C59EDCBFB28Q36302339-7DB4398B-5C57-4750-B8C5-B6BBC6E6EF67Q36477727-C45815BC-9A08-48E0-9B37-451A638F7E32Q36512551-570E7FE3-9029-4F40-9ACF-3A69B4394A93Q36557850-1681D2EF-9EC8-4890-B98B-1F71533B006FQ36632217-C4E841D9-89A9-4FD6-B0AB-EF16856E267EQ36674705-565A1A8D-3CFD-4945-80FA-07CE5497DB41Q36683742-B39024A3-148A-4B86-8896-8D23CBE72710Q36765795-23578435-EFA9-4E8B-B569-59066A452D9AQ36796516-F8686B4D-A347-42A1-9F62-7A3ECBADF019Q36802561-5D1AADCF-2B72-402E-BD89-A721E36E2AA9Q36813063-520046C6-FCFF-4B5F-907C-0AA5C2A10E1FQ36848480-00869B18-FD15-4C8A-8B71-BD93D9404295Q36886275-B21B6A96-C70D-4D77-8B56-98C846FFFA61Q36931450-F7FD6009-3DEC-4CF9-A36A-5CE3D4577CF3
P2860
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Continuous intravenous dobutam ...... omized Survival Trial (FIRST).
@en
Continuous intravenous dobutam ...... onal Randomized Survival Trial
@nl
type
label
Continuous intravenous dobutam ...... omized Survival Trial (FIRST).
@en
Continuous intravenous dobutam ...... onal Randomized Survival Trial
@nl
prefLabel
Continuous intravenous dobutam ...... omized Survival Trial (FIRST).
@en
Continuous intravenous dobutam ...... onal Randomized Survival Trial
@nl
P2093
P50
P1476
Continuous intravenous dobutam ...... omized Survival Trial (FIRST).
@en
P2093
Adams KF Jr
Gheorghiade M
Grossman SH
McKenna WJ
McNulty SE
O'Connor CM
Uretsky BF
P356
10.1016/S0002-8703(99)70250-4
P407
P433
P577
1999-07-01T00:00:00Z